Anzeige
Meldung des Tages: Die nächsten 10.000 Bohrmeter könnten alles verändern, während andere Explorer noch planen

VolitionRX News

Aktie
WKN:  A12B6K ISIN:  US9286611077 US-Symbol:  VNRX Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
0,1998 $
+0,00 $
0,00%
0,17311 € 09.03.26
Depot/Watchlist
Marktkapitalisierung *
22,85 Mio. €
Streubesitz
62,90%
KGV
-1,94
Index-Zuordnung
-

VolitionRX News

09.10.25 - PR Newswire
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants PR Newswire
02.10.25 - PR Newswire
Volition Sponsors Upcoming GenomeWeb Webinar
Volition Sponsors Upcoming GenomeWeb Webinar PR Newswire
29.09.25 - PR Newswire
Volition Signs Co-Marketing and Services Agreement with Hologic
Volition Signs Co-​Marketing and Services Agreement with Hologic PR Newswire
09.09.25 - PR Newswire
Volition Signs First Human Out Licensing Deal
Volition Signs First Human Out Licensing Deal PR Newswire
14.08.25 - PR Newswire
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update PR Newswire
08.08.25 - PR Newswire
VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update PR Newswire
04.08.25 - PR Newswire
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering
VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering PR Newswire
16.07.25 - PR Newswire
Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation
Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation PR Newswire
08.07.25 - PR Newswire
Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes
Volition Announces Groundbreaking Lateral Flow Test for Point-​of-Care Quantification of Nucleosomes PR Newswire
12.06.25 - PR Newswire
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure PR Newswire
04.06.25 - PR Newswire
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties PR Newswire
19.05.25 - PR Newswire
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats PR Newswire
15.05.25 - PR Newswire
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update PR Newswire
12.05.25 - PR Newswire
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update PR Newswire
07.05.25 - PR Newswire
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption PR Newswire
31.03.25 - PR Newswire
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update PR Newswire
28.03.25 - PR Newswire
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 PR Newswire
27.03.25 - PR Newswire
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 PR Newswire
26.03.25 - PR Newswire
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering PR Newswire
25.03.25 - PR Newswire
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update PR Newswire

Newssuche

Videos

newspaper
10.03.26 -10,03%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »